Semaglutide vs Tirzepatide — at a glance

Both are weekly injectables for weight loss, both work on incretin hormones, both are widely researched. But they’re not interchangeable. Semaglutide is a single-receptor GLP-1 agonist; Tirzepatide is a dual-receptor agonist that hits GLP-1 and GIP. That mechanism difference shows up in efficacy data, side-effect profile, dosing scale, and how each behaves in real research protocols.

Property	Semaglutide	Tirzepatide
Mechanism	GLP-1 agonist	Dual GLP-1 / GIP agonist
Brand names	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound
Standard dose ladder	0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg
Frequency	Once weekly SubQ	Once weekly SubQ
Plasma half-life	~7 days	~5 days
Trial weight loss (68 wk, top dose)	~14.9% (STEP-1, Wegovy)	~22.5% (SURMOUNT-1, 15 mg)
Vial size (research)	2–10 mg lyo	10–30 mg lyo
GI side-effect profile	Significant, dose-dependent	Similar, slightly less per mg
Cardio outcome data	SUSTAIN-6, SELECT — established	SURPASS-CVOT — ongoing, early positive

Mechanism difference — why dual-agonism matters

Semaglutide binds and activates the GLP-1 receptor. That receptor sits on pancreatic beta cells (boosting insulin), in the hypothalamus (suppressing appetite), and in the gut (slowing gastric emptying). One target, three useful downstream effects.

Tirzepatide hits the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP itself has historically been overlooked — early studies suggested it wasn’t useful as a weight-loss target alone. But combined with GLP-1 stimulation, GIP appears to enhance the satiety and metabolic effects of GLP-1 while modestly improving the side-effect profile per unit of weight lost. Whether that’s because GIP buffers some of GLP-1’s GI effects, or because the dual signal recruits more downstream pathways, is still being debated in the literature.

Practically: same mechanism family, one extra receptor. That extra receptor seems to be why Tirzepatide produces larger weight loss at the top trial doses.

Efficacy — what the trials show

Semaglutide (STEP-1, 2.4 mg weekly, 68 weeks): mean weight loss 14.9% from baseline in non-diabetic participants with obesity.

Tirzepatide (SURMOUNT-1, 15 mg weekly, 72 weeks): mean weight loss 22.5% from baseline in the same population. At 10 mg, mean loss was 19.5%. At 5 mg, 15.0% — already matching Semaglutide’s top dose.

The simplest read: Tirzepatide produces ~50% more weight loss than Semaglutide at top doses. But individual variability is huge — some participants on Semaglutide lose 25%+ and some on Tirzepatide lose 8%. The headline numbers are means, not destinies.

Side effects — practically identical, slightly different intensity

Effect	Semaglutide	Tirzepatide
Nausea	40–45% of users, dose-dependent	30–35% of users
Diarrhoea	30%	20%
Constipation	25%	20%
Sulfur burps	Common	Common
Injection-site reaction	~5%	~5%
Pancreatitis (rare)	Boxed warning	Boxed warning
Thyroid C-cell concern	Boxed warning (animal data)	Boxed warning (animal data)

Net: same kinds of side effects, Tirzepatide slightly easier to tolerate per mg in the published data. Anecdotal research-community reports lean the same direction, though selection bias makes that hard to weight properly.

Dosing in practice — research protocols

The dose ladders look very different by mg but they’re functionally aligned at the receptor level. Semaglutide is more potent per mg — 2.4 mg is the top dose. Tirzepatide goes up to 15 mg because each Tirz milligram does less per mg than each Sema milligram, on aggregate.

Both follow the same titration logic: start low, hold for 4 weeks, step up, repeat. Skipping a step or going up too fast is the most common reason for severe GI side effects. The published cheat sheet — free GLP-1 reconstitution PDF — has every titration step and reconstitution math for both compounds.

Switching protocols — Semaglutide to Tirzepatide

Many research participants switch from Semaglutide to Tirzepatide after plateauing. The clean protocol:

• Wait one week after the last Semaglutide dose. Their half-lives are comparable, so this window keeps you from stacking GLP-1 receptor activation.
• Start Tirzepatide at 2.5 mg — not at an “equivalent” dose. The receptor binding is different enough that matching by mg is wrong. Re-titrate from the bottom.
• Hold 4 weeks at 2.5 mg before stepping to 5 mg. The retitration usually feels milder than the first Sema titration did — your gut is already adapted.
• Track weight + tolerance at each step. If Tirz at 7.5 mg already exceeds your best Sema response, that’s your new maintenance — no need to push up to 15.

Which one’s right for your research?

Choose Semaglutide if:

• You want the more-studied option — Sema has a decade of trial data, established cardio outcome benefit, and clearer safety signals at scale.
• You’re optimising for cost — Sema is typically cheaper per mg of research-grade vial.
• You’re sensitive to GI side effects — Sema’s effects are well-mapped and the slower escalation is easier to manage at the bottom of the ladder.
• Your target is modest weight loss (10–15%), not extreme.

Choose Tirzepatide if:

• You want maximum effect size and your tolerance can handle escalating doses.
• You’ve plateaued on Semaglutide and want to push past the 15% range.
• You’re researching glycaemic-control endpoints — Tirz beats Sema in head-to-head HbA1c data (SURPASS-2).
• You can source it reliably — Tirz research-grade availability has been more variable than Sema historically.

Cost, availability, and sourcing

At the prescription level, Tirzepatide is currently more expensive than Semaglutide in most markets — newer compound, single manufacturer (Eli Lilly), narrower production base. At the research-grade vial level the gap narrows but Tirz still trends 20–40% more per mg of total compound.

Both compounds are widely available from UK / EU research suppliers. Our partner DR Peps stocks both with third-party COA verification on every batch. Before buying from anyone, run their COA through the vendor trust guide checklist.

Frequently asked questions

Can I stack Semaglutide and Tirzepatide?

Generally no. Both fully agonise the GLP-1 receptor, so stacking them adds dose-dependent side effects without adding receptor activation — the receptor is already saturated. The exception is the CagriSema research direction: Semaglutide stacked with Cagrilintide (an amylin analogue with different receptor binding) shows additive effects. Sema + Tirz doesn’t.

Which has worse sulfur burps?

Reports are anecdotal but Tirzepatide trends slightly milder on this specific side effect. Both produce sulfur burps via the same mechanism — delayed gastric emptying letting food sit in the stomach longer, producing hydrogen sulfide as gut bacteria work on it. Smaller meals, slower escalation, and avoiding high-sulfur foods (eggs, broccoli, red meat) helps with either compound.

What about Retatrutide?

Retatrutide is the next-generation triple agonist (GLP-1 / GIP / glucagon). Phase 2 trial data shows ~24% weight loss at 12 mg over 48 weeks, larger than either Sema or Tirz at equivalent durations. Still investigational — not approved, less safety data, supply less reliable. See our separate Retatrutide vs Tirzepatide comparison.

Can I switch back from Tirzepatide to Semaglutide?

Yes, but uncommon — most people who switch up don’t switch back. If you do, wait one week, start Sema at a step that roughly matches the response you had on Tirz (not the mg). If 10 mg Tirz held you at maintenance, 1 mg Sema is a reasonable starting equivalence. Re-titrate from there.

Which has better cardio outcome data?

Semaglutide, by years. The SELECT trial (2023) showed Semaglutide reduces major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease — the first weight-loss drug to do so. Tirzepatide’s equivalent trial (SURPASS-CVOT) is ongoing — early signals positive but full data not yet published.

Related

Full compound pages: Semaglutide, Tirzepatide. Category overview: Weight Loss & Metabolic Research Compounds. Free PDF: GLP-1 Reconstitution Cheat Sheet — every titration schedule, every reconstitution maths, side-effect timeline.